Trial Profile
Alzheimer's disease patients using Exelon ® (4.6mg/24h, 5cm2) transdermal patch; effect of skinfold thickness
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- 18 Aug 2015 New trial record
- 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.